Dominique Koensgen-Mustea

Sorafenib plus topotecan versus placebo plus topotecan for platinum-resistant ovarian cancer (TRIAS): a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial

Radoslav Chekerov, Felix Hilpert, Sven� Mahner, Ahmed El‐Balat et autres

de (code pays fourni par la source)

Preference of elderly patients’ to oral or intravenous chemotherapy in heavily pre-treated recurrent ovarian cancer: final results of a prospective multicenter trial

Radoslav Chekerov, Philipp Harter, Stefan Fuxius, Lars Hanker et autres

BACKGROUND: Palliative systemic treatment in elderly gynaecological cancer patients remains a major challenge. In recurrent ovarian cancer (ROC), treosulfan an active alkylating drug showed similar cytotoxicity whether as oral (p.o.) or intravenous (i.v.) application. The aim of this innovative trial was to …

de (code pays fourni par la source)

Tumorerkrankungen in der Gynäkologie – Ovarialkarzinom

Dominique Koensgen-Mustea

Prediction of intestinal tumor involvement by parameters of nutritional status in patients with primary / recurrent ovarian cancer

PM Skowronek, Marc Kuhberg, FCK Chen, Dominique Koensgen-Mustea et autres

Introduction: Global malnutrition is widespread among patients with ovarian cancer. The objective of this prospective study was to investigate the influence of tumor localisation and stage on nutritional status of patients with ovarian cancer. Material/ Methods: Between 04.2007 and 03.2008, 75 patients …

de (code pays fourni par la source)

Operative Therapie beim Ovarialkarzinomrezidiv

Jalid Sehouli, Christina Fotopoulou, Gülten Oskay-Özcelik, Dominique Koensgen-Mustea et autres

de (code pays fourni par la source)

P158 PREDICTION OF INTESTINAL TUMOR INVOLVEMENT BY PARAMETERS OF NUTRITIONAL STATUS IN PATIENTS WITH PRIMARY OR RECURRENT OVARIAN CANCER

Marc Kuhberg, P. Skowronek, F. Chen, Dominique Koensgen-Mustea et autres